Archives of physical medicine and rehabilitation · 2025
Systematic Review on Norepinephrine and Dopamine Reuptake Inhibitors for Traumatic Brain Injury-Related Symptoms: Report of the American Congress of Rehabilitation Medicine.
СтатьяСистематический обзорПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Seel Ronald T, Arciniegas David B, Macciocchi Stephen P, Cifu David X, Frazier Yelena Goldin, Kaelin Darryl L, Katz Douglas I, Oyesanya Tolu O, Pourrahmat Masoud, Schofield Thomas, Wagner Amy K, Fazeli Mir Sohail
Аннотация
OBJECTIVE: To evaluate the efficacy of mixed norepinephrine and dopamine reuptake inhibitors on cognitive and noncognitive neuropsychiatric outcomes after traumatic brain injury (TBI), and to describe their safety/tolerability.
DATA SOURCES: A literature search using MEDLINE and a reference title search were conducted from inception to August 17, 2023.
STUDY SELECTION: Studies were retained based on prespecified, Participants, Intervention, Comparator, Outcome framework criteria: (1) participants were aged ≥18 years with mild, moderate, or severe TBI; (2) an mixed norepinephrine and dopamine reuptake inhibitors class medication was studied (eg, methylphenidate hydrochloride [MPH]); (3) the research design included a comparison group; (4) the treatment sample size was ≥9; and (5) cognition, emotion, behavior, or safety/tolerability was an outcome.
DATA EXTRACTION: Trained methodologists extracted information. Each study's scientific quality was classified using procedures in the 2017 American Academy of Neurology Guideline Development and Process Manual; articles with class I to III evidence ratings were retained. Thirteen articles from 442 identified publications met review criteria.
DATA SYNTHESIS: Sufficient evidence was available to evaluate MPH. Meta-analysis generated pooled effects and 95% CIs for outcome domains. MPH improved performance on objective measures of processing speed (k=9, d=0.39 [95% CI, 0.17-0.60), selective attention (k=5, d=0.33 [95% CI, 0.04-0.61]), and sustained attention (k=4, d=0.45 [95% CI, 0.11-0.79]). MPH reduced clinician-evaluated depressive symptoms (k=2, d=1.06 [95% CI, 0.47-1.64). MPH did not produce adverse events or clinically significant autonomic dysfunction. There was little evidence that time since injury and injury severity moderated MPH effects.
CONCLUSIONS: Among adults with TBI, MPH has medium effects on selective attention, sustained attention, and processing speed, and large effects on depressive symptoms. These effects are consistent with MPH's biological mechanisms and are not moderated by injury severity or time since injury.
DATA SOURCES: A literature search using MEDLINE and a reference title search were conducted from inception to August 17, 2023.
STUDY SELECTION: Studies were retained based on prespecified, Participants, Intervention, Comparator, Outcome framework criteria: (1) participants were aged ≥18 years with mild, moderate, or severe TBI; (2) an mixed norepinephrine and dopamine reuptake inhibitors class medication was studied (eg, methylphenidate hydrochloride [MPH]); (3) the research design included a comparison group; (4) the treatment sample size was ≥9; and (5) cognition, emotion, behavior, or safety/tolerability was an outcome.
DATA EXTRACTION: Trained methodologists extracted information. Each study's scientific quality was classified using procedures in the 2017 American Academy of Neurology Guideline Development and Process Manual; articles with class I to III evidence ratings were retained. Thirteen articles from 442 identified publications met review criteria.
DATA SYNTHESIS: Sufficient evidence was available to evaluate MPH. Meta-analysis generated pooled effects and 95% CIs for outcome domains. MPH improved performance on objective measures of processing speed (k=9, d=0.39 [95% CI, 0.17-0.60), selective attention (k=5, d=0.33 [95% CI, 0.04-0.61]), and sustained attention (k=4, d=0.45 [95% CI, 0.11-0.79]). MPH reduced clinician-evaluated depressive symptoms (k=2, d=1.06 [95% CI, 0.47-1.64). MPH did not produce adverse events or clinically significant autonomic dysfunction. There was little evidence that time since injury and injury severity moderated MPH effects.
CONCLUSIONS: Among adults with TBI, MPH has medium effects on selective attention, sustained attention, and processing speed, and large effects on depressive symptoms. These effects are consistent with MPH's biological mechanisms and are not moderated by injury severity or time since injury.